Aclaris Therapeutics, Inc. (ACRS)

Market Cap	451.03M +126.0%
Revenue (ttm)	7.83M -58.2%
Net Income	-64.92M
EPS	-0.53
Shares Out	120.60M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,407,082
Open	3.610
Previous Close	3.660
Day's Range	3.520 - 3.795
52-Week Range	1.050 - 4.890
Beta	0.87
Analysts	Strong Buy
Price Target	9.75 (+160.7%)
Earnings Date	May 7, 2026

About ACRS

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 7, 2015
• Employees: 73
• Stock Exchange: NASDAQ
• Ticker Symbol: ACRS
• Website: https://www.aclaristx.com

Financial Performance

In 2025, Aclaris Therapeutics's revenue was $7.83 million, a decrease of -58.19% compared to the previous year's $18.72 million. Losses were -$64.92 million, -50.84% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for ACRS stock is "Strong Buy." The 12-month stock price target is $9.75, which is an increase of 160.70% from the latest price.

Price Target

$9.75

(160.70% upside)

Analyst Consensus: Strong Buy